Company intelligence / Profile preview

Fursan Capital

Riyadh, Riyadh, Saudi Arabia

Ownership: Private
Development stage: Other

Overview

Fursan Capital is a Riyadh-based private equity firm that focuses on strategic investments in the healthcare and pharmaceutical sectors within the Middle East. The firm is most notable for its majority acquisition and subsequent development of Avalon Pharma (Middle East Pharmaceutical Industries Company), a leading regional manufacturer of generic drugs and cosmeceuticals. Fursan Capital provides growth capital and strategic oversight to help its portfolio companies scale operations and expand their geographic footprint across the GCC. Their investment approach targets sectors with high growth potential driven by regional demographic shifts and healthcare privatization. The firm played a key role in preparing Avalon Pharma for its successful public listing on the Saudi Exchange in 2024.

Industry: Investors

Beyond the preview

Go deeper on Fursan Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fursan Capital.

Explore the full profile